Beam Therapeutics (BEAM) EBT (2019 - 2026)
Beam Therapeutics (BEAM) reported EBT of -$97.3 million for Q1 2026, up 11.03% year-over-year from -$87.7 million in Q1 2025, and down 139.85% on a QoQ basis from $244.3 million in Q4 2025.
Beam Therapeutics (BEAM) has 8 years of EBT data on file, last reported at -$97.3 million in Q1 2026.
- Quarterly EBT rose 11.03% year-over-year to -$97.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$68.1 million (up 82.43% YoY) and the FY2025 annual result came in at -$80.0 million, up 78.77% from the prior year.
- EBT eased to -$97.3 million in Q1 2026 per BEAM's latest filing, from $244.3 million in the prior quarter.
- Across five years, EBT topped out at $244.3 million in Q4 2025 and bottomed at -$112.7 million in Q3 2025.
- The 5-year median for EBT is -$90.4 million (2024), against an average of -$55.6 million.
- The widest annual swing landed in 2022, when EBT tumbled 190.44%; it then jumped 485.99% in 2023.
- Tracing BEAM's EBT over 5 years: stood at -$37.3 million in 2022, then jumped by 485.99% to $144.2 million in 2023, then sank by 162.67% to -$90.4 million in 2024, then soared by 370.38% to $244.3 million in 2025, then slumped by 139.85% to -$97.3 million in 2026.
- Per Business Quant, the three latest BEAM EBT figures stand at -$97.3 million (Q1 2026), $244.3 million (Q4 2025), and -$112.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Beam Therapeutics | 3.40 Bn | 3.40 Bn | - | -97.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -97.35 Mn |
| Dec 31, 2025 | 244.30 Mn |
| Sep 30, 2025 | -112.73 Mn |
| Jun 30, 2025 | -102.29 Mn |
| Mar 31, 2025 | -109.42 Mn |
| Dec 31, 2024 | -90.35 Mn |
| Sep 30, 2024 | -96.67 Mn |
| Jun 30, 2024 | -91.01 Mn |
| Mar 31, 2024 | -92.28 Mn |
| Dec 31, 2023 | 144.16 Mn |
| Sep 30, 2023 | -96.09 Mn |
| Jun 30, 2023 | -82.78 Mn |
| Mar 31, 2023 | -88.97 Mn |
| Dec 31, 2022 | -37.35 Mn |
| Sep 30, 2022 | -81.67 Mn |
| Jun 30, 2022 | -79.91 Mn |
| Mar 31, 2022 | -75.58 Mn |
| Dec 31, 2021 | -64.71 Mn |
| Sep 30, 2021 | -28.12 Mn |
| Jun 30, 2021 | -59.03 Mn |
| Mar 31, 2021 | -200.39 Mn |
| Dec 31, 2020 | -40.76 Mn |
| Sep 30, 2020 | -37.15 Mn |
| Jun 30, 2020 | -26.04 Mn |
| Mar 31, 2020 | -27.76 Mn |
| Dec 31, 2019 | -26.05 Mn |
| Sep 30, 2019 | -17.41 Mn |
| Jun 30, 2019 | -16.86 Mn |
| Mar 31, 2019 | -12.61 Mn |